The “ever-vaccinated” stock–flow bias in adult RSV vaccine policy evaluation: A methodological caution and a flow-based remedy
= .008 post hoc, did not persist); these underpowered analyses are illustrative only, not identified for the policy effect. To our knowledge, this is the first portable flow-metric operationalization for survey and registry data, released as open code. Registry data exploratorily show the stock metric can obscure equity monitoring (Gini 0.210→0.202; range 39.7→43.5 pp; not significant). As a mid-season snapshot, these figures are an upper bound on the end-of-season value; the conclusion that coverage is dominated by prior-season stock holds through the season. RSV policy evaluation should pre-specify current-season flow as the primary outcome and report the stock share as a strongly recommended diagnostic.
Authors
- Ling Chen (ORCID: https://orcid.org/0000-0001-7699-4820)
- Weiping Deng (ORCID: https://orcid.org/0009-0006-3774-7644)
Publication Details
- Journal
- Human Vaccines & Immunotherapeutics
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1080/21645515.2026.2755223
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00